Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer : Evidence to date
Copyright © 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved..
ROS proto-oncogene 1 (ROS1) encodes a type I integral membrane protein with tyrosine kinase activity and whose activating alterations are involved in the aggressiveness of several tumor types. Fusions involving ROS1 gene are present in 1-2% of lung adenocarcinomas and other solid tumors. Entrectinib, also known as RXDX-101, is a potent second-generation, multitarget oral inhibitor against NTRK1, NTRK2, NTRK3, ALK, and ROS1 with the ability to cross the blood-brain barrier. Results of Phase I and II trials have led the Food and Drug Administration to grant approval to entrectinib for the treatment of patients with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). In this review, we will describe the biology of ROS1, as well as results of the efficacy and safety of different clinical trials evaluating entrectinib in ROS1-positive NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Hematology/oncology and stem cell therapy - 14(2021), 3 vom: 07. Sept., Seite 192-198 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Araujo, Jhajaira M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.09.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hemonc.2020.11.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318563258 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318563258 | ||
| 003 | DE-627 | ||
| 005 | 20231225165617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hemonc.2020.11.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318563258 | ||
| 035 | |a (NLM)33290717 | ||
| 035 | |a (PII)S1658-3876(20)30177-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Araujo, Jhajaira M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer |b Evidence to date |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a ROS proto-oncogene 1 (ROS1) encodes a type I integral membrane protein with tyrosine kinase activity and whose activating alterations are involved in the aggressiveness of several tumor types. Fusions involving ROS1 gene are present in 1-2% of lung adenocarcinomas and other solid tumors. Entrectinib, also known as RXDX-101, is a potent second-generation, multitarget oral inhibitor against NTRK1, NTRK2, NTRK3, ALK, and ROS1 with the ability to cross the blood-brain barrier. Results of Phase I and II trials have led the Food and Drug Administration to grant approval to entrectinib for the treatment of patients with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). In this review, we will describe the biology of ROS1, as well as results of the efficacy and safety of different clinical trials evaluating entrectinib in ROS1-positive NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug safety | |
| 650 | 4 | |a Entrectinib | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 7 | |a Benzamides |2 NLM | |
| 650 | 7 | |a Indazoles |2 NLM | |
| 650 | 7 | |a MAS1 protein, human |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Mas |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ROS1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a entrectinib |2 NLM | |
| 650 | 7 | |a L5ORF0AN1I |2 NLM | |
| 700 | 1 | |a Gomez, Andrea C |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Joseph A |e verfasserin |4 aut | |
| 700 | 1 | |a Rolfo, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Raez, Luis E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology/oncology and stem cell therapy |d 2008 |g 14(2021), 3 vom: 07. Sept., Seite 192-198 |w (DE-627)NLM194209520 |x 2589-0646 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:3 |g day:07 |g month:09 |g pages:192-198 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hemonc.2020.11.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 3 |b 07 |c 09 |h 192-198 | ||